ArticleFrontiers in immunology2026
A multi-machine learning framework identifies novel PANoptosis-related biomarkers and their immune landscape in ulcerative colitis: Insights from transcriptomics and experimental validation.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ulcerative colitis (UC), a persistent inflammatory bowel disorder, has witnessed a gradual increase in its global incidence in recent years. This study aims to identify biomarkers linked to PANoptosis in UC, highlighting a pressing requirement to identify novel diagnostic biomarkers and therapeutic targets for improved UC management. Methods: Differentially expressed genes (DEGs) in UC were identified using R software through Gene Expression Omnibus (GEO) GSE87466 and GSE206285 datasets integration. Weighted Gene Co-expression Network Analysis (WGCNA) was employed to uncover co-expression modules. PANoptosis-related hub genes were selected using eight machine learning algorithms, followed by validation of the diagnostic markers with five machine learning algorithms in test datasets GSE38713 and GSE47908. A nomogram incorporating these six genes was subsequently constructed. Comprehensive analyses-including correlation assessment, single-cell profiling, gene set enrichment analysis (GSEA), and immune infiltration evaluation-were performed to characterize their functional relevance. Their expression profiles were further validated through DSS-induced mouse UC model. Results: Six potential biomarkers (ECSCR, IRF1, MMP1, PPARG, S100A8, S100A9) were identified, demonstrating significant upregulation or downregulation in UC. KEGG and GO enrichment analyses indicated these genes are significantly implicated in bacterial infection, immune response, and inflammation pathways. Analysis of immune cell infiltration uncovered distinct shift in immune cell composition in UC patients, correlating with the identified biomarkers. The single-cell analysis indicated that IRF1 was predominantly expressed in smooth muscle cells, while S100A8 and S100A9 showed markedly high expression in neutrophils. In the DSS-induced mouse model, all six biomarkers showed significant expression, which was consistent with their expression patterns in clinical samples. Conclusions: This study effectively discovers six PANoptosis-related biomarkers with potential diagnostic value for UC, emphasizing their role in disease progression and immune regulation, offering new biomarkers for the early diagnosis and personalized treatment of UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.